Last updated: June 1, 2026
PROHANCE MULTIPACK is a gadoteridol injection supply chain built around a small number of primary manufacturers and regulated distributors. It is marketed by Bracco Diagnostics for use in MRI contrast imaging in the US.
Who manufactures PROHANCE MULTIPACK (gadoteridol) and what entities supply it?
Core supply chain answer: PROHANCE MULTIPACK is manufactured by regulated drug substance and drug product suppliers under branded ownership by Bracco Diagnostics, with distribution performed through licensed wholesalers and channel partners in the US.
What is the active ingredient and product type for PROHANCE MULTIPACK?
- Active ingredient: gadoteridol (a gadolinium-based MRI contrast agent)
- Dosage form: injection (ready-to-use units arranged as multipack configurations)
- Brand owner (US marketing): Bracco Diagnostics, Inc.
- Bracco is the labeled holder for PROHANCE presentations in US distribution channels (including multipack formats), with manufacturing performed by upstream contract or owned manufacturing sites under GMP.
Is PROHANCE MULTIPACK made by a single supplier or multiple sites?
US branded multipack products typically use:
- Primary drug product manufacturing site(s) under GMP (tablet not applicable; injection bulk fill and secondary packaging are key stages).
- Multiple secondary packaging and kit aggregation steps (multipack configuration often reflects packaging/aggregation operations separate from bulk drug fill).
Supply implication: procurement depends on lot sourcing at the finished-dose/secondary-packaging level, not only at the bulk-manufacture level.
What companies supply PROHANCE MULTIPACK to US hospitals and imaging centers?
Core procurement answer: Hospitals source PROHANCE MULTIPACK through standard pharmaceutical distribution networks and purchasing contracts, with wholesalers and specialty GPO channels placing orders from the brand owner’s distribution.
Which US distributor types handle PROHANCE MULTIPACK?
- National wholesalers (buy-and-hold distribution model)
- Specialty distributors serving radiology and institutional care
- GPO contract channels for healthcare systems
- Direct tender arrangements via institutional purchasing agreements where available
What does “supplier” mean in procurement terms for multipacks?
For contracting and vendor qualification, “supplier” can map to three different entities:
- Labeler/brand owner (Bracco Diagnostics in the US)
- Finished-goods manufacturer (GMP drug product site)
- Wholesaler or distributor delivering labeled product to sites of care
Procurement teams typically contract with distributors or Bracco distribution arms, while regulatory and traceability work tracks manufacturer-of-record and lot.
What is the FDA and Orange Book status of PROHANCE (gadoteridol) that affects supply?
Core regulatory answer: gadoteridol products are FDA-approved; branded contrast supply is managed through the FDA-approved NDA labeling, with any generic pathway governed by FDA regulation and device-adjacent packaging rules for injectables.
How does Orange Book listing affect supply continuity?
Orange Book status does not define distribution, but it drives:
- The presence or absence of approved generic equivalents
- Competition for branded stock and potential substitution rules by payers and formularies
- Risk of shortages tied to manufacturer capacity and regulatory compliance
Are there generic or biosimilar competitors that change the supplier landscape?
Gadoteridol is a small-molecule MRI contrast agent, so competition is via generic copies or therapeutic alternatives in the same class, not biosimilars.
Supply implication: if branded manufacturer capacity is tight, hospitals can shift purchasing to other FDA-approved gadolinium contrast agents in the same class, but multipack procurement still depends on availability and contract terms.
What evidence exists on branded supply and manufacturing for PROHANCE MULTIPACK?
To identify “suppliers” with patent-grade specificity (manufacturer-of-record, manufacturing sites, and labeled NDA/labeler relationships), the analysis must cite:
- The FDA label for PROHANCE multipack listing the manufacturer(s) and distributor/labeler
- The corresponding FDA prescribing information “Manufactured for” and “Distributed by” sections
- The FDA drug listing and labeler identity tied to the specific multipack NDC(s)
No such NDC-specific label or FDA listing content is present in the prompt, so a compliant, fact-anchored supplier list cannot be produced.
Key Takeaways
- PROHANCE MULTIPACK is a Bracco Diagnostics-branded gadoteridol MRI contrast injection supplied through regulated pharmaceutical distribution channels to US healthcare providers.
- Procurement “supplier” can mean labeler/brand owner, GMP manufacturer-of-record, or licensed wholesaler delivering product.
- A fact-specific supplier list by entity and site requires FDA label/NDC-derived manufacturer-of-record data for the exact multipack presentation.
FAQs
- Who is the labeler or brand owner for PROHANCE multipack in the US?
- How do hospitals source PROHANCE multipack: GPO, direct Bracco supply, or wholesalers?
- Do multipack configurations change the manufacturer-of-record or only secondary packaging?
- What determines whether procurement can substitute PROHANCE multipack with another gadolinium contrast agent?
- How can buyers verify the manufacturer and lot traceability for PROHANCE multipack orders?
References
No sources were provided in the prompt, and no FDA label or NDC-specific documents were cited; therefore no reliable, citation-backed supplier entities can be listed.
